Ziconotide for treatment of severe chronic pain

The Lancet

Volumn 375, Issue 9725, 2010, Pages 1569-1577

  Schmidtko, Achim ^a   Lötsch, Jörn ^a   Freynhagen, Rainer ^b   Geisslinger, Gerd ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Benedictus Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; MORPHINE; OMEGA CONOTOXIN MVIIA; PLACEBO;

AGITATION; ANAPHYLAXIS; APNEA; ATAXIA; BRADYCARDIA; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTINUOUS INFUSION; DELIRIUM; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DEPENDENCE; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; HALLUCINATION; HUMAN; HYPERSENSITIVITY; MEMORY DISORDER; MENTAL DISEASE; NAUSEA; NYSTAGMUS; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SUICIDE; UNRESPONSIVENESS; URINE RETENTION; VERTIGO; VOMITING;

EID: 77951652246     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60354-6     Document Type: Review

References (65)

1. Alford D.P., Liebschutz J., Chen I.A., et al. Update in pain medicine. J Gen Intern Med 23 (2008) 841-845
2. Breivik H., Collett B., Ventafridda V., Cohen R., and Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10 (2006) 287-333
3. Scholz J., and Woolf C.J. Can we conquer pain?. Nat Neurosci 5 suppl (2002) 1062-1067
4. O'Connor A.B., and Dworkin R.H. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 122 suppl (2009) 22-32
5. Kroenke K., Krebs E.E., and Bair M.J. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 31 (2009) 206-219
6. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291 (2004) 63-70
7. Deer T., Krames E.T., Hassenbusch S., et al. Future directions for intrathecal pain management: a review and update from the interdisciplinary Polyanalgesic Consensus Conference 2007. Neuromodulation 11 (2008) 92-97
8. Deer T., Krames E., Hassenbusch S., et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 10 (2007) 300-328
9. Heading C.E. Conus peptides and neuroprotection. Curr Opin Investig Drugs 3 (2002) 915-920
10. Olivera B.M. Conus peptides: biodiversity-based discovery and exogenomics. J Biol Chem 281 (2006) 31173-31177
11. Olivera B.M., Gray W.R., Zeikus R., et al. Peptide neurotoxins from fish-hunting cone snails. Science 230 (1985) 1338-1343
12. Stix G. A toxin against pain. Sci Am 292 (2005) 70-75
13. Olivera B.M., and Teichert R.W. Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. Mol Interv 7 (2007) 251-260
14. Wallace M.S. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 6 (2006) 1423-1428
15. Miljanich G.P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11 (2004) 3029-3040
16. Olivera B.M., Cruz L.J., de Santos V., et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 26 (1987) 2086-2090
17. Miljanich G.P., and Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol 35 (1995) 707-734
18. McGivern J.G. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today 11 (2006) 245-253
19. Vacher H., Mohapatra D.P., and Trimmer J.S. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev 88 (2008) 1407-1447
20. Gohil K., Bell J.R., Ramachandran J., and Miljanich G.P. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res 653 (1994) 258-266
21. Schmidtko A., Tegeder I., and Geisslinger G. No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci 32 (2009) 339-346
22. Motin L., and Adams D.J. ω-Conotoxin inhibition of excitatory synaptic transmission evoked by dorsal root stimulation in rat superficial dorsal horn. Neuropharmacology 55 (2008) 860-864
23. Ji R.R., Kohno T., Moore K.A., and Woolf C.J. Central sensitization and LTP: do pain and memory share similar mechanisms?. Trends Neurosci 26 (2003) 696-705
24. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp Brain Res 147 (2002) 456-463
25. Yokoyama K., Kurihara T., Makita K., and Tanabe T. Plastic change of N-type Ca channel expression after preconditioning is responsible for prostaglandin E2-induced long-lasting allodynia. Anesthesiology 99 (2003) 1364-1370
26. 2+ channel-deficient mice. Genes Brain Behav 6 (2007) 375-388
27. Field M.J., Cox P.J., Stott E., et al. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 103 (2006) 17537-17542
28. Luo Z.D., Chaplan S.R., Higuera E.S., et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21 (2001) 1868-1875
29. Taylor C.P. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel α2-δ[Cavα2-δ] ligands. Pain 142 (2009) 13-16
30. Bowersox S.S., and Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 36 (1998) 1651-1658
31. Snutch T.P. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2 (2005) 662-670
32. Wallace M.S., Charapata S.G., Fisher R., et al., for the Ziconotide Nonmalignant Pain Study 96-002 Group. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9 (2006) 75-86
33. Rauck R.L., Wallace M.S., Leong M.S., et al., the Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 31 (2006) 393-406
34. National PBM drug monograph: Ziconotide for intrathecal infusion (Prialt) (December, 2006). http://www.pbm.va.gov/Clinical%20Guidance/Drug%20Monographs/Ziconotide,% 20Monograph.pdf (accessed March 25, 2009).
35. EMEA. Scientific discussion of ziconotide (2005). http://www.emea.europa.eu/humandocs/PDFs/EPAR/Prialt/14122704en6.pdf (accessed March 25, 2009).
36. Webster L.R., Fisher R., Charapata S., and Wallace M.S. Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 37 (2009) 363-372
37. Wallace M.S., Rauck R., Fisher R., Charapata S.G., Ellis D., Dissanayake S., and for the Ziconotide 98-022 Study Group. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 106 (2008) 628-637
38. Webster L.R., Fakata K.L., Charapata S., Fisher R., and MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 9 (2008) 282-290
39. Yaksh T.L. Ziconotide: a viewpoint by Tony L Yaksh. CNS Drugs 20 (2006) 340-341
40. Newcomb R., Abbruscato T.J., Singh T., Nadasdi L., Davis T.P., and Miljanich G. Bioavailability of Ziconotide in brain: influx from blood, stability, and diffusion. Peptides 21 (2000) 491-501
41. Wermeling D.P. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 25 (2005) 1084-1094
42. Thompson J.C., Dunbar E., and Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 9 (2006) 147-152
43. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. Int J Clin Pharmacol Ther 44 (2006) 478-483
44. Williams J.A., Day M., and Heavner J.E. Ziconotide: an update and review. Expert Opin Pharmacother 9 (2008) 1575-1583
45. Wallace M.S., Kosek P.S., Staats P., Fisher R., Schultz D.M., and Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 9 (2008) 271-281
46. Wang Y.X., Gao D., Pettus M., Phillips C., and Bowersox S.S. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 84 (2000) 271-281
47. Wermeling D., Drass M., Ellis D., et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 43 (2003) 624-636
48. Lynch S.S., Cheng C.M., and Yee J.L. Intrathecal ziconotide for refractory chronic pain. Ann Pharmacother 40 (2006) 1293-1300
49. Rauck R.L., Wallace M.S., Burton A.W., Kapural L., and North J.M. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract 9 (2009) 327-337
50. Kapural L., Lokey K., Leong M.S., et al. Intrathecal ziconotide for complex regional pain syndrome: seven case reports. Pain Pract 9 (2009) 296-303
51. Stanton-Hicks M., and Kapural L. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide. J Pain Symptom Manage 32 (2006) 509-511
52. Smith H.S., and Deer T.R. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag 5 (2009) 521-534
53. McGuire D., Bowersox S., Fellmann J.D., and Luther R.R. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 30 (1997) 400-403
54. 2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25 (2004) 465-470
55. Bell T.J., Thaler C., Castiglioni A.J., Helton T.D., and Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 41 (2004) 127-138
56. Feng Z.P., Doering C.J., Winkfein R.J., Beedle A.M., Spafford J.D., and Zamponi G.W. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J Biol Chem 278 (2003) 20171-20178
57. Yamamoto T., and Takahara A. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 9 (2009) 377-395
58. Hu L.Y., Ryder T.R., Rafferty M.F., et al. Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties. J Med Chem 42 (1999) 4239-4249
59. Seko T., Kato M., Kohno H., et al. Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. Bioorg Med Chem Lett 11 (2001) 2067-2070
60. Seko T., Kato M., Kohno H., et al. L-Cysteine based N-type calcium channel blockers: structure-activity relationships of the C-terminal lipophilic moiety, and oral analgesic efficacy in rat pain models. Bioorg Med Chem Lett 12 (2002) 2267-2269
61. Yamamoto T., Niwa S., Iwayama S., et al. Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity. Bioorg Med Chem 14 (2006) 5333-5339
62. Yamamoto T., Niwa S., Ohno S., et al. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg Med Chem Lett 16 (2006) 798-802
63. Meng G., Wu N., Zhang C., et al. Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence. Eur J Pharmacol 586 (2008) 130-138
64. Koganei H., Shoji M., and Iwata S. Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. Biol Pharm Bull 32 (2009) 1695-1700
65. Zamponi G.W., Feng Z.P., Zhang L., et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett 19 (2009) 6467-6472